Lung Cancer Archives - Cancer Therapy Advisor

New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.

Underdosing in Patients With Cancer and Obesity: A Thing of the Past?

By

Agata Boxe

June 16, 2021

New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.

This frontal view x-ray of the chest shows advanced stage non-small cell lung cancer (NSCLC) of a 50-year-old woman with a long history of smoking and emphysema. The orange area depicts collapsed lung tissue at the base of the right lung, and the yellow area highlights a pleura-based density along the right hemithorax.

ASCO 2021 Lung Cancer In-depth

Pasireotide Plus Everolimus Improves PFS in Advanced Neuroendocrine Tumors of the Lung or Thymus

By

Mark L. Fuerst

June 14, 2021

The median PFS was 8.5 months in the pasireotide arm, 12.5 months in the everolimus arm, and 16.5 months in the combination arm.

MRI scan of the abdomen highlighting small cell lung cancer (SCLC).

ASCO 2021 Lung Cancer In-depth

PD-L1 Expression in Macrophage-Like Cells Linked to PFS After Immunotherapy in Non-Small Cell Lung Cancer

By

Mark L. Fuerst

June 11, 2021

The size of cancer-associated macrophage-like cells was linked to progression-free survival as well.

PD-1/PD-L1 inhibitors offer an improvement over standard of care in SCLC, but there is still a long way to go.

ASCO 2021 Lung Cancer In-depth

No Survival Difference With Once-Daily vs Twice-Daily Radiotherapy in Small Cell Lung Cancer

By

Mark L. Fuerst

June 9, 2021

Overall and progression-free survival were similar between the treatment arms.

Men with GPS scores greater than 40 had a poor disease prognosis after surgery and their disease was likely to behave like that of high-risk patients.

ASCO 2021

Radiotherapy and Surgery Produce Comparable Outcomes in Operable Stage IA Non-Small Cell Lung Cancer

By

Leah Lawrence

June 7, 2021

Survival results were similar with stereotactic ablative radiotherapy and surgery.

ASCO 2021

Less Pain, Fewer Complications With VATS vs Open Surgery in Early-Stage Lung Cancer

By

Leah Lawrence

June 7, 2021

Quality of life outcomes were superior with video-assisted thoracoscopic surgery.

The MET alteration occurs in 3% to 4% of patients with the condition.

ASCO 2021

Surgical Data Support Nivolumab Plus Chemotherapy for Resectable NSCLC

By

Leah Lawrence

June 6, 2021

The neoadjuvant regimen showed higher rates of definitive surgery and minimally invasive approach.

The NSCLC treatment pipeline includes additional targeted therapies, immunotherapies, and chemothera

ASCO 2021

Adding Chemotherapy to Immunotherapy Improves Survival in Advanced Non-Small Cell Lung Cancer

By

Sucharita Mistry, PhD

June 5, 2021

Progression-free and overall survival were superior in patients who received immunotherapy and chemotherapy.

ASCO 2021

Low-Grade Immune-Related Adverse Events Linked to Prolonged Survival in NSCLC

By

Sucharita Mistry, PhD

June 5, 2021

Patients who experienced immune-related adverse events had longer overall survival than those who did not in both the atezolizumab-containing and control arms.

Xiuning Le, MD, PhD, discusses the future of tepotinib in the treatment of NSCLC. Dr Le is an author of a phase 2 study on tepotinib, a highly selective MET inhibitor.

ASCO 2021

New First-Line Treatment Option for NSCLC: Nivolumab + Ipilimumab + Chemotherapy

By

Sucharita Mistry, PhD

June 5, 2021

First-line treatment with nivolumab in combination with ipilimumab and chemotherapy provided durable survival compared with chemotherapy alone in patients with NSCLC.